3rd Annual AFDD Summit

Memo

With 3 days of in-depth cutting-edge case studies and the highest calibre of industry and academic discussions, 3rd Anti-fibrotic Drug Development Summit (AFDD) will provide the roadmap to anti-fibrotic drug development success. Hear from pharma and biotech companies of all sizes, as well as clinicians and leading academics for a complete picture of the current challenges and opportunities. Find commonalities across disease areas that can be applied back at the lab with presentations from specialists across all fibrotic conditions including NASH, IPF, CKD, cardiovascular, gastro-intestinal, Scleroderma, rare disease and ocular fibrosis. On Monday November 18, 2019 at 8:30 am (ends Wednesday November 20, 2019 at 4:30 pm) Prices: Conference + Workshop Day: USD 3997.00,Conference Only: USD 2899.00,Workshop Only: USD 1299.00 URLs: Tickets: https://go.evvnt.com/482147-2?pid=5569 Brochure: https://go.evvnt.com/482147-3?pid=5569 Speakers: Zoe Johnson, Chief Scientific Officer, iOnctura, Lisa Hazelwood, Principal Scientist Liver Disease and Fibrosis Discovery, Abbvie, John Atkinson, Senior Research Scientist Tissue Remodelling, UCB, Richard Stratton, Consultant Physician and Honorary Senior Lecturer, University College London, Glenn Rosen, Senior Vice President Preclinical Translational Sciences Small Molecule, Coherus Biosciences, Matthew Breyer, Distinguished Scientist CVM, Janssen, Tim Johnson, Director Immunology Therapeutic Area, UCB, Ravi Kumar, Senior Vice President and Chief Scientific Officer, Acceleron Pharma, Pieter Muntendam, Chief Executive Officer and Founder, G3 Pharmaceuticals, Aftab Taiyab, Research Scientist, McMaster University, Kirby von Kessler, Associate Director Clinical Development, Lung Biotechnology, Masha Poyurovsky, Vice President Discover Biology, Kadmon Corporation LLC, Alexey Lugovskoy, Chief Development Officer, Morphic Therapeutics, Sten R. Sörensen, Chief Executive Officer, Cereno Scientific, Shervin Assassi, Professor of Medicine and Co-Director of the UTHealth Scleroderma Program, University of Texas Health Science Center at Houston, Robert Lafyatis, Adjunct Professor Medicine, Boston University, Anie Philip, Professor Department of Surgery, Research Institute of the McGill University Health Center, Yaron Ilan, Director Department of Medicine, Hebrew University Hadassah Medical Center, Sydney Montesi, Instructor in Medicine, Harvard University, Ganesh Raghu, Professor Medicine in the Division of Pulmonary and Critical Care Medicine, University of Washington, Min Lu, Head of Fibrosis, Morphic Therapeutics, Rozsa Schlenker – Herceg, Executive Director Clinical Research, Medical Affairs and Respiratory, Boehringer-Ingelheim, Rick Keenan Ph.D., Chief Scientific Officer, OptiKira, Moustapha El-Amine, Director Global Search and Evaluate, AstraZeneca, Weilin Xie, Senior Principal Scientist, Celgene Corporation, Eliezer Zomer Ph.D., Vice President Drug Discovery and Manufacturing, Galectin Therapeutics, Lee Borthwick, Fibrosis Biology Lecturer and Chief Operating Officer FibroFind, Newcastle University, Jean-Francois Thibodeau, Research Scientist, Prometic Biosciences, Gilles Tremblay, Director Preclinical Development, Forbius, Scott Macdonnell, Senior Staff Scientist, Regeneron, Mehran Moghaddam, Chief Executive Officer, OROX Biosciences, Scott Turner, Vice President Translational Sciences, Pliant Therapeutics, Emily Offer, Principal Scientist and Team Leader, Redx Immunology, Komathi Stem, Chief Executive Officer, MonArc Bionetworks, Bertram Pitt, University of Michigan School of Medicine, Professor of Medicine Emeritus, Rana Herro, Junior Faculty Instructor, La Jolla Institute for Immunology, Resat Cinar, Staff Scientist, National Institute on Alcohol Abuse and Alcoholism, Robert Edwards, Director and CVM Clinical Project Specialist, Johnson and Johnson Venue details: Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States